Local administration of recombinant IL-1β and IL-12 fully restored anti-tumor T cell responses in P2RX7−/−, NLRP3−/− and Caspase-1−/− mice [21], suggesting that the use of biologics may potentially benefit patients that have defects in these pathways. This evidence concerns the gene IL1B and neoplasm.